Evidence map›Paper›PMID 40136377›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.

Eva Laverdure, Luigina Mollica, Imran Ahmad, Sandra Cohen, Silvy Lachance, Olivier Veilleux, Maryse Bernard, Eve-Lyne Marchand, Jean-Sébastien Delisle, Lea Bernard and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Eva LaverdureDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0001-8722-8419
Luigina MollicaDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.
Imran AhmadDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0003-1899-0164
Sandra CohenDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.
Silvy LachanceDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0001-7882-9335
Olivier VeilleuxDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0002-7029-1769
Maryse BernardFaculty of Medicine, Université de Montréal, Montréal, QC H2V 0B3, Canada.ORCID 0009-0007-5510-5036
Eve-Lyne MarchandFaculty of Medicine, Université de Montréal, Montréal, QC H2V 0B3, Canada.ORCID 0009-0005-0618-3260
Jean-Sébastien DelisleDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0003-1460-7287
Lea BernardDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.
Mélissa BoileauDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.
Tony PetrellaFaculty of Medicine, Université de Montréal, Montréal, QC H2V 0B3, Canada.ORCID 0000-0002-7099-8107
Sarah-Jeanne PilonFaculty of Medicine, Université de Montréal, Montréal, QC H2V 0B3, Canada.
Philippe BouchardDepartment of Pharmacy, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, QC H1T 2M4, Canada.ORCID 0000-0003-0635-6086
Denis-Claude RoyDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0002-5921-1692
Lambert BusqueDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.ORCID 0000-0002-5375-3749
Isabelle FleuryDepartment of Medicine, Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, l, Montréal, QC HIT 2M4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One challenge of chimeric antigen receptor T-cell therapy (CAR-T) for relapsed or refractory large B-cell lymphoma (LBCL) is achieving disease control during manufacturing. We report real-word outcomes of 100 patients treated with axicabtagene ciloleucel (axi-cel,

Indexed as

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenAdultAgedAged, 80 and overBiological ProductsFemaleHumansMaleMiddle AgedReceptors, Antigen, T-CellTreatment OutcomeYoung Adultaxicabtagene ciloleucelBiological ProductsReceptors, Antigen, T-CellReceptors, Chimeric Antigentisagenlecleucelbridging therapyCAR-Tlarge B-cell lymphomaradiation therapy

Identifiers

PMID40136377
PMCPMC11941054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.